Simcere Pharmaceuticals
Simcere Pharmaceuticals
Overview
Simcere Pharmaceuticals Inc. headquartered in Nanjing, China, is an incorporated pharmaceutical company producing a wide range of quality generic medicines. It is one of the top 100 Chinese Pharmaceutical companies.
The Company's products are well sold in 80% area all over the China. The Company was established in 1995 and group is divided into six parts: Jiangsu Simcere Pharmaceuticals Co. Ltd, Simcere Pharmaceuticals Co. Ltd, Nanjing Simcere Doyea Pharmaceutical Co. Ltd, Shanghai Simcere Pharmaceuticals Co. Ltd, Jiangsu Simcere Pharmaceuticals R&D Co. Ltd. Shandong Simcere Yantai Medgenn Co., Ltd.
Simcere aggressively pursues the internationalization of its business. The growth strategy is to not only focusing on enhancing the market share in China but also exploring the opportunities in the overseas market. The Company has a strong brand marketing team and distribution network in China.
A new state-of-the-art R&D building is currently under constructing in the suburb of Nanjing, China and will be completed at the end of 2006.Simcere is one of the most aggressive investors on R&D in the Chinese pharmaceutical industry with an annual spending accounting some proportion of its sales. The Company research focuses on the areas of Oncology, Cardiovascular & Cerebrovascular, etc.
Simcere's continued focus on R&D has resulted in several significant approvals in domestic markets. The Company has a promising pipeline and a very impressive clinical trial network. To accelerate its research program, Simcere has joined hands with various research and academic organizations such as Tsinghua University, Shanghai No.2 Medical University, Tianjin Drug Research Institute, Nanjing University of Science and Technology, Sichuan Antibiotics Research Institute in the areas of drug discovery and development.
Simcere's commitment in R&D has led to several commercially successful stories. Edaravone Injection, brand name: Bicun ; (the first launch in China and second one in the World) has achieved 17.9 Million USD sales in 2005.
The Company has recently successfully entered into strategic investment partnership with Hony Capital- the investment arm of the world famous computer maker Lenovo.
In order to build up an effective strategic decision making system and internationalized management expertise, Simcere Group will be undergoing a tremendous learning process with Lenovo together.
Together with the commitment of around 2000 strong talented and professional workforce, Simcere continues to aggressively implement its strategies to become the first echelon pharmaceutical company in China
R&D
Overview
Our R&D is the core competence to achieve our sustainable business growth
Simcere R&D company is staffed by over 100 highly qualified professionals of multidisciplines graduated from national and international famous universities and academies. In order to satisfy the need of research, they are divided into several teams.
Pharmaceutical Synthesis Platform
Pharmaceutical Formulation Platform
Pharmaceutical Analysis Platform
Traditional Chinese Medicine Process Research Platform
Our research labs are armed with superior equipment and facilities, including multireactor, automatic fraction collector, rotary vacuum evaporator, high-pressure reactor, medium scale formulation instruments, high pressure homogenization, particle size instrument, HPLC, GC, IR spectroscopy, UV spectroscopy and traditional Chinese medicine extraction instruments. Apart from this, we also have the access to expensive equipment such as NMR, MS and Powder X-ray Diffraction within our contracted labs. For example, Analysis Center in China Pharmaceutical University, Modern Analysis Center in Nanjing University and Physical Chemistry Analysis Center in Nanjing Normal University.
Additionally, R&D company has its own fully qualified and experienced clinical research team proficient in GCP standard operation and pharmacy regulations. The clinical research team has a good co-operation relationship with all 60 GCP standard national clinical research bases covering departments of neurology, respiration system, cardiovascular & cerebrovascular diseases, pediatrics, gynecology, gastroenterology, endocrinology, rheumatology, otolaryngology and oncology.
Contact Us
Tel: 0086-25-85477000-310
R&D Fax: 0086-25-85472579
International Business Department Fax: 0086-25-85472579
Votes:11
Comments: 0